Stocktoria
Scienture Holdings, Inc. SCNX
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2020-02-18
Scienture Holdings, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $431,609 | $136,643 | $1.4M | $10.3M | $9.9M | $17.1M | $7.4M | $3.8M | $2.9M | $2.5M |
| Gross profit | $331,482 | $6,005 | $49,030 | $5.5M | $4.7M | $5.7M | $4.9M | $3.4M | $2.9M | $2.5M |
| R&D expense | $2.0M | $2.2M | — | — | — | — | — | — | — | — |
| Operating income | -$42.6M | -$14.7M | -$4.4M | -$2.9M | -$5.3M | -$2.5M | $125,224 | -$87,616 | $395,095 | -$1.0M |
| Interest expense | — | — | $1.2M | $336,206 | $23,590 | $29,389 | $53,227 | $57,541 | $157,056 | $151,500 |
| Income tax | -$2.0M | -$534,396 | — | — | — | — | — | — | — | — |
| Net income | -$41.5M | $9.1M | -$17.8M | -$3.5M | -$5.3M | -$2.5M | -$284,428 | $9,038 | $288,983 | -$2.8M |
| EPS (diluted) | $-2.70 | $2.48 | $-23.35 | $-6.13 | $-0.65 | — | $-0.05 | $0.00 | $0.01 | $-0.09 |
| Operating cash flow | -$13.4M | -$14.3M | $3.6M | -$1.5M | -$2.6M | -$2.2M | $141,775 | $273,386 | $171,670 | -$503,529 |
| Free cash flow | — | -$14.3M | — | — | -$2.6M | -$2.3M | — | — | — | — |
| Cash & equivalents | $6.7M | — | $361 | $1.1M | $3.1M | $5.9M | $2.9M | $869,557 | $183,914 | $14,679 |
| Inventory | $213,408 | — | $968 | $65,523 | $56,279 | $1.3M | $56,761 | $79,966 | — | — |
| Total assets | $84.2M | $104.9M | $12.5M | $3.7M | $5.8M | $9.8M | $5.6M | $2.2M | $617,476 | $337,124 |
| Total liabilities | $14.1M | $25.8M | $12.0M | $3.4M | $2.0M | $1.1M | $1.4M | $1.4M | $929,409 | $1.5M |
| Shareholders' equity | $70.1M | $79.1M | $542,353 | $763,136 | $3.8M | $8.7M | $4.1M | $844,668 | -$311,933 | -$1.1M |
Growth · year-over-year · Revenue CAGR -17.7%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +215.9% | -90.0% | -86.7% | +3.6% | -42.2% | +130.3% | +94.1% | +30.7% | +18.1% | -14.8% |
| Net income growth | -557.9% | — | — | — | — | — | -3247.0% | -96.9% | — | — |
| EPS growth | -208.9% | — | — | — | — | — | — | -100.0% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.